Back to Journals » Drug Design, Development and Therapy » Volume 7

Current and emerging pharmacological treatments for sarcoidosis: a review

Authors Beegle SH, Barba K, Gobunsuy R, Judson MA

Received 29 January 2013

Accepted for publication 9 March 2013

Published 12 April 2013 Volume 2013:7 Pages 325—338

DOI https://doi.org/10.2147/DDDT.S31064

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Scott H Beegle,1 Kerry Barba,2 Romel Gobunsuy,1 Marc A Judson1

1Division of Pulmonary and Critical Care Medicine, 2Department of Medicine, Albany Medical College, Albany, NY, USA

Abstract: The treatment of sarcoidosis is not standardized. Because sarcoidosis may never cause significant symptoms or organ dysfunction, treatment is not mandatory. When treatment is indicated, oral corticosteroids are usually recommended because they are highly likely to be effective in a relative short period of time. However, because sarcoidosis is often a chronic condition, long-term treatment with corticosteroids may cause significant toxicity. Therefore, corticosteroid sparing agents are often indicated in patients requiring chronic therapy. This review outlines the indications for treatment, corticosteroid treatment, and corticosteroid sparing treatments for sarcoidosis.

Keywords: pulmonary sarcoidosis, extrapulmonary sarcoidosis, treatment, drugs, corticosteroids

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]